Pd-Rx Pharmaceutical
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services. In addition, the company offers a dispensing platform, a manual dispensing s… Read more
Market Cap & Net Worth: Pd-Rx Pharmaceutical (PDRX)
Pd-Rx Pharmaceutical (PINK:PDRX) has a market capitalization of $4.49 Million ($4.49 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #43402 globally and #13894 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pd-Rx Pharmaceutical's stock price $2.62 by its total outstanding shares 1715090 (1.72 Million).
Pd-Rx Pharmaceutical Market Cap History: 2015 to 2025
Pd-Rx Pharmaceutical's market capitalization history from 2015 to 2025. Data shows change from $4.92 Million to $4.49 Million (-4.30% CAGR).
Pd-Rx Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pd-Rx Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.24x
Pd-Rx Pharmaceutical's market cap is 0.24 times its annual revenue
0.29x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.97 Million | $21.47 Million | $507.67K | 0.23x | 9.79x |
| 2017 | $6.17 Million | $25.99 Million | $626.97K | 0.24x | 9.84x |
| 2018 | $8.95 Million | $24.97 Million | $621.16K | 0.36x | 14.41x |
| 2019 | $6.26 Million | $20.87 Million | -$12.92K | 0.30x | N/A |
| 2020 | $4.72 Million | $21.03 Million | -$384.14K | 0.22x | N/A |
| 2021 | $4.29 Million | $21.60 Million | $1.86 Million | 0.20x | 2.31x |
| 2022 | $10.29 Million | $28.72 Million | $3.03 Million | 0.36x | 3.39x |
| 2023 | $12.01 Million | $21.27 Million | -$98.06K | 0.56x | N/A |
| 2024 | $6.19 Million | $18.95 Million | -$753.50K | 0.33x | N/A |
| 2025 | $4.49 Million | $18.35 Million | -$257.52K | 0.24x | N/A |
Competitor Companies of PDRX by Market Capitalization
Companies near Pd-Rx Pharmaceutical in the global market cap rankings as of March 18, 2026.
Key companies related to Pd-Rx Pharmaceutical by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #165 globally with a market cap of $115.21 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #350 globally with a market cap of $62.31 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #430 globally with a market cap of $50.81 Billion USD.
- Sigma Healthcare Limited (OTCGREY:SIGGF): Ranked #1462 globally with a market cap of $12.16 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | McKesson Corporation | NYSE:MCK | $115.21 Billion | $941.89 |
| #350 | Cencora Inc. | NYSE:COR | $62.31 Billion | $334.71 |
| #430 | Cardinal Health Inc | NYSE:CAH | $50.81 Billion | $216.36 |
| #1462 | Sigma Healthcare Limited | OTCGREY:SIGGF | $12.16 Billion | $1.88 |
Pd-Rx Pharmaceutical Historical Marketcap From 2015 to 2025
Between 2015 and today, Pd-Rx Pharmaceutical's market cap moved from $4.92 Million to $ 4.49 Million, with a yearly change of -4.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.49 Million | -27.42% |
| 2024 | $6.19 Million | -48.43% |
| 2023 | $12.01 Million | +16.67% |
| 2022 | $10.29 Million | +140.00% |
| 2021 | $4.29 Million | -9.09% |
| 2020 | $4.72 Million | -24.66% |
| 2019 | $6.26 Million | -30.08% |
| 2018 | $8.95 Million | +45.06% |
| 2017 | $6.17 Million | +24.21% |
| 2016 | $4.97 Million | +1.01% |
| 2015 | $4.92 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Pd-Rx Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.49 Million USD |
| MoneyControl | $4.49 Million USD |
| MarketWatch | $4.49 Million USD |
| marketcap.company | $4.49 Million USD |
| Reuters | $4.49 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.